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Introduction {#sec1}
============

Cellular senescence is a stress response, resulting in stable cell cycle arrest, tumor suppression, aging, and wound healing ([@bib4], [@bib10], [@bib17], [@bib43]). Aberrant activation of the Ras oncogene triggers oncogene-induced senescence (OIS), conferring a precancerous state ([@bib14], [@bib40]). OIS is an *in vivo* tumor suppressor mechanism ([@bib8], [@bib47]) with the p53 and Rb/p16 pathways as major mediators of senescence induction and maintenance ([@bib20], [@bib40]). OIS is characterized by multiple phenotypical changes, such as heterochromatic foci ([@bib3], [@bib11], [@bib13], [@bib20], [@bib31]) and the senescence-associated secretory phenotype (SASP) ([@bib1], [@bib12], [@bib24]). Through the secretion of extracellular matrix proteases, interleukins, and chemokines, OIS cells recruit immune cells, mediating their own clearance. SASP has been implicated in cancer initiation ([@bib45]) by creating an inflammatory pro-tumorigenic microenvironment. SASP factors play a role in cellular reprogramming ([@bib30], [@bib38]) and contribute to aging and tissue degeneration ([@bib33], [@bib41]). SASP acts in a paracrine fashion to induce secondary senescence in surrounding cells ([@bib2]). Paracrine secondary senescence is thought to enhance immune surveillance and to act as a failsafe mechanism minimizing chances of retaining damaged cells ([@bib2], [@bib24], [@bib32]). Recently, ectopic Notch pathway activation has been implicated as an intermediate phenomenon during primary senescence induction, resulting in a distinct secretome ([@bib16]). The role of Notch in secondary OIS mediation remains undescribed.

Here, we use single-cell RNA sequencing (scRNA-seq) to decipher the heterogeneity within OIS populations. Our single-cell experiments reveal two distinct transcriptional endpoints in primary senescence, separated by their activation of Notch, with secondary senescent cells uniformly progressing to an endpoint characterized by Notch activation *in vivo* and *in vit*ro. We confirm Notch-mediated senescence as an essential mediator of secondary, juxtacrine senescence in OIS.

Primary and Secondary Senescence Have Distinct Transcriptomes {#sec1.1}
-------------------------------------------------------------

To investigate dynamic changes and cell-cell heterogeneity in OIS, we performed a scRNA-seq time course experiment before and after 2, 4, and 7 days of RasV12 induction, using H-RasG12V-induced IMR90 (ER:IMR90) fibroblasts ([@bib48]) and the Smart-Seq2 protocol ([@bib35]) ([Figure 1](#fig1){ref-type="fig"}A). After stringent filtering ([Figure 1](#fig1){ref-type="fig"}B; [Figures S1](#mmc1){ref-type="supplementary-material"}A--S1D; [Table S1](#mmc2){ref-type="supplementary-material"}), we obtained a final cell count of 100/288 for day 0, 41/96 for day 2, 42/96 for day 4, and 41/288 for day 7 for downstream analysis ([Figure S1](#mmc1){ref-type="supplementary-material"}D). To confirm a senescence phenotype at day 7, we profiled bromodeoxyuridine (BrdU) incorporation (37/390 cells \[9%\]), senescence associated heterochromatic focis (SAHF; 265/390 cells \[68%\]), and senescence-associated beta-galactosidase (SA-Beta Gal) (428/523 cells \[82%\]) ([Figure S1](#mmc1){ref-type="supplementary-material"}E). To assess time-dependent changes in the transcriptome, we ordered cells along a pseudo-temporal trajectory based on differential gene expression between growing and senescence (adjusted p \< 0.05; [Table S2](#mmc3){ref-type="supplementary-material"} ([Figure 1](#fig1){ref-type="fig"}C) ([@bib18]). Using Monocle2 ([@bib36]), we found a continuous progression from growing to senescence, with days 2 and 4 cells as intermediates and two distinct senescent populations ([Figure 1](#fig1){ref-type="fig"}C), suggesting two facultative, alternative endpoints. To determine whether RasV12 activation led to the split into two senescence populations ([Figure 1](#fig1){ref-type="fig"}C), we overlaid RasV12 expression onto the monocle plot ([Figures 1](#fig1){ref-type="fig"}B and 1C; [Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G; [Table S3](#mmc4){ref-type="supplementary-material"}). RasV12-expressing cells ([Figure 1](#fig1){ref-type="fig"}C; Ras+, round symbols) progressed to both senescence endpoints with a 21:4 skew toward the cluster designated OIS. Fibroblasts without detectable RasV12 expression uniformly progressed to the cluster tentatively designated secondary senescence, suggesting it as the obligate endpoint (cross symbols, Ras−; [Figure 1](#fig1){ref-type="fig"}C; Fisher's exact test, 1.64 × 10^−6^). Our inability to detect RasV12 in a subset of senescent cells suggests that senescence was induced as a secondary event. We verified HRAS as one of the top predicted upstream regulators for the senescence top population (p = 3.1 × 10^−34^) by using Ingenuity pathway analysis (IPA, QIAGEN; [Figure S1](#mmc1){ref-type="supplementary-material"}H). We confirmed a senescence phenotype for both populations by upregulation of key senescence genes ([Figure 1](#fig1){ref-type="fig"}D) cyclin-dependent kinase 1a (*CDKN1A*) and cyclin-dependent kinase inhibitor 2b (*CDKN2B*) and SASP factors interleukin 8 (*IL8*), interleukin 6 (*IL6*), and interleukin 1B (*IL1B*) (p \< 0.05 for all genes; [Figure 1](#fig1){ref-type="fig"}D). To verify two major senescence populations transcriptome-wide, we used a consensus clustering approach, SC3 ([@bib22]), with the number of clusters determined by silhouette plot ([@bib39]) ([Figure S1](#mmc1){ref-type="supplementary-material"}I). SC3 detected two senescence clusters largely overlapping with the subpopulations obtained by Monocle2 (cluster 1 16/21 or 76% RasV12+ cells, cluster 4 11/15 or 73% RasV12− cells), supporting the notion that the split into two senescence populations is based on the absence or presence of RasV12 ([Figure 1](#fig1){ref-type="fig"}E). To verify that populations observed are due to primary OIS and secondary senescence, we co-cultured ER:IMR90 with IMR90:GFP fibroblasts (10:1), where secondary senescence is induced in IMR90:GFP-positive cells ([@bib2]). We generated scRNA-seq data before and 7 days after RasV12 activation by using the 10× Genomics Chromium ([Figure 1](#fig1){ref-type="fig"}F).Figure 1Secondary Senescent Cells Only Partially Resemble Paracrine-Induced Senescence(A) Schematic representation of the time course experiment.(B) Number of senescent cells with reads mapping to the G \> T mutation site of *RAS* gene.(C) Monocle2 plot for time course experiment. The presence of the mutated *RAS* gene is indicated. Pie charts for the percentage of Ras+/Ras− cells in the top and bottom clusters.(D) Boxplots for the expression of senescence genes in the time course experiment. The top and bottom bounds of the boxplot correspond to the 75th and 25th percentile, respectively. p values were obtained using differential analysis in SCDE.(E) Unsupervised clustering using SC3 for senescent cells. Cells were annotated as either OIS (top senescence branch, purple), secondary senescence (bottom branch, green), or NA (neither, pink).(F) Schematic representation of the co-culture experiment.(G) t-Distributed Stochastic Neighbor Embedding (tSNE) visualization of co-culture scRNA-seq.(H) tSNE visualization of single cells grouped into 3 clusters.(I) Boxplots for the expression of senescence genes in the co-culture experiment. The top and bottom bounds of the boxplot correspond to the 75th and 25th percentile, respectively. p values were obtained using differential analysis in SCDE.(J) Integration analysis of the two senescence clusters from time course and co-culture experiments.(K) Overlap of differentially expressed (DE) genes between paracrine/OIS, time course, and co-culture experiments.Related to [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S1. Alignment Rates and Quality Control of RNA Sequencing Data, Related to Figures 1 and 4](#mmc2){ref-type="supplementary-material"}, [Table S2. Differential Expression of RNA Sequencing Data, Related to Figures 1, 2, 3, and 4](#mmc3){ref-type="supplementary-material"}, [Table S3. Presence of Construct and qPCR Primer, Related to Figures 1, 2, 3, and 4](#mmc4){ref-type="supplementary-material"}, [Table S4. Genes for Venn Diagrams, Related to Figures 1 and 2](#mmc5){ref-type="supplementary-material"}.

Senescence was confirmed on sorted populations by qPCR ([Figure S1](#mmc1){ref-type="supplementary-material"}J) and SA-Beta Gal staining for primary and secondary senescent cells ([Figure S1](#mmc1){ref-type="supplementary-material"}K). Cells were annotated based on GFP, RasV12 expression, and the G \> T mutation of *Ras* gene ([Figure 1](#fig1){ref-type="fig"}G). We identified three distinct clusters using Seurat and Sparcl ([@bib9], [@bib46]), namely growing (blue dots), secondary senescence (GFP positive, black dots) and OIS (RasV12 positive, red dots), with significant enrichment for the OIS and secondary senescence populations (chi-square test, p = 4.1 × 10^−14^; [Figure 1](#fig1){ref-type="fig"}H). The secondary senescence cluster also contained a minor population of RasV12-expressing cells. This mirrors our earlier findings, confirming two facultative senescence endpoints for primary RasV12 senescent cells, with GFP-positive secondary senescent cells showing a uniform distribution. Senescence genes were upregulated in both senescent clusters, including *CDKN1A*, *CDKN2B*, and *IL8* ([Figure 1](#fig1){ref-type="fig"}I; [Table S2](#mmc3){ref-type="supplementary-material"}) and long-term stable cell cycle arrest confirmed at 21 days post co-culture ([Figure S1](#mmc1){ref-type="supplementary-material"}L). When overlaying transcriptomes of the time course and the co-culture experiments, a significant number of cells identified as OIS and secondary senescence (GFP and part of RasV12) clustered together ([Figure 1](#fig1){ref-type="fig"}J; chi-square test, p \< 0.05). The co-clustering by senescent signatures was achieved despite the data being generated by 10× or Smart-Seq2. In summary, we identified two major transcriptional endpoints in primary OIS, whereas secondary senescent cells were uniformly assigned.

Paracrine senescence is thought to be the main effector mechanism for secondary, cell extrinsic senescence induction ([@bib2], [@bib24]). To test if the secondary senescence cluster is explained by a paracrine signature, we overlaid bulk RNA-seq data ([@bib2]). Although we found a significant overlap with paracrine genes (hypergeometric test: paracrine/OIS and time course secondary senescence/OIS (Ras−/Ras+) p \< 0.001; paracrine/OIS and 10× secondary senescence/OIS p \< 0.001, 10× secondary senescence/OIS and time course secondary senescence/OIS (Ras−/Ras+) p \< 0.001; [Figure 1](#fig1){ref-type="fig"}K; [Table S4](#mmc5){ref-type="supplementary-material"}), a large fraction of genes shared between our two single cell experiments remained unexplained, suggesting the involvement of additional pathways in secondary senescence.

The Transcriptome of Secondary and a Subset of Primary Senescent Cells Is Characterized by Notch {#sec1.2}
------------------------------------------------------------------------------------------------

Because the secondary senescence clusters were only partially characterized by a paracrine senescence signature, we explored consistent differences between the secondary senescence and the primary OIS clusters. We assessed the most differentially expressed genes and detected fibrillar collagens (collagen 1A1, 3A1, and 5A2; [Figure 2](#fig2){ref-type="fig"}A). Downregulation of fibrillar collagens is consistently observed in senescence ([@bib16]), but they failed to downregulate in the secondary senescence cluster ([Table S2](#mmc3){ref-type="supplementary-material"}; [Figure 2](#fig2){ref-type="fig"}A). A similar failure to downregulate collagens was reported in a specialized primary senescence phenotype, induced by ectopic, temporal activation of Notch ([@bib16]). The same report suggested that the secretome in RasV12-induced senescence was regulated by CCAAT-enhancer-binding protein beta (CEBPB), with Notch-induced senescence relying on transforming growth factor beta (TGFB) ([Figure 2](#fig2){ref-type="fig"}B) ([@bib16]). Several lines of evidence identify a notch-induced senescence (NIS) signature in the secondary senescence cluster. First, IPA pathway analysis identifies TGFB1 as exclusively activated in the secondary senescence clusters compared to growing or the primary OIS ([Figure 2](#fig2){ref-type="fig"}C). In contrast, RELA and IL1B pathways, regulators of the CEBPB transcriptome, were differentially activated in primary OIS clusters ([Figure 2](#fig2){ref-type="fig"}C). Consistent with our RasV12 annotation, HRAS was exclusively activated in primary OIS ([Figure 2](#fig2){ref-type="fig"}C; [Figure S2](#mmc1){ref-type="supplementary-material"}A). Second, we profiled candidate genes involved in Notch signaling and TGFB activation. When plotting TGFB-induced transcript 1, (*TGFB1I1*) with Notch-target connective tissue growth factor (*CTGF*) and *CEBPB*, we identified a significant (p \< 0.05) upregulation of *CTGF* and *TGFB1I1* genes in the secondary senescence cluster with a simultaneous downregulation of CEBPB, significant on the protein but not mRNA level ([Figures 2](#fig2){ref-type="fig"}D and 2E; p = 0.016), resembling the TGFB and CEBPB bias in NIS. This bias was confirmed by qPCR ([Figure 2](#fig2){ref-type="fig"}D; TGFB1 p = 0.02, TGFBI p = 0.05).Figure 2Secondary Senescence Comprises NIS Signature in the Majority of Cells(A) Boxplots for the expression of genes *COL1A1*, *COL3A1*, and *COL5A2* in the time course and co-culture experiments (p \< 0.05). The top and bottom bounds of the boxplots correspond to the 75th and 25th percentile, respectively. p values were obtained using differential analysis in SCDE.(B) Model suggesting NIS and RIS are regulated by Notch1 through TGFB and CEBPB, respectively.(C) IPA analysis of the two senescence clusters from the time course and co-culture experiments relative to growing.(D) Boxplots for the expression of *TGFB1I1*, *CTGF*, and *CEBPB* genes in the time course (top) and co-culture experiments (middle). The top and bottom bounds of the boxplot correspond to the 75th and 25th percentile, respectively. p values were obtained using differential analysis in SCDE. Bar graphs denoting expression of *TGFB1* (n = 6), *TGFBL* (n = 6), and *CEBPB* (n = 3) mRNA as measured by qPCR in OIS and GFP cells (bottom) (TGFB1: t = −3.2317, df = 5.5117, p = 0.02; TGFBI: t = −2.2567, df = 9.8141, p = 0.05; CEBPB: t = 0.068192, df = 3.2294, p = 0.95, unpaired Student's t test. Error bars represent SEM).(E) Representative image of GFP (secondary senescence) and CEBPB (red) immunofluorescence in the co-culture experiment. Mean intensity for primary (ER:Ras) and secondary senescent cells (GFP) was measured (p = 0.016, unpaired Student's t test). Error bars are displayed as SEM.(F) GSEA plots for the enrichment of secondary and primary OIS DE genes (time course and co-culture experiments) in [@bib16] NIS and RIS log2FC preranked genes. Normalized enrichment score (NES) and false discovery rate (FDR) are shown.(G) Venn diagrams overlapping expression signatures from time course (top) and co-culture (bottom) with NIS signature genes. (Secondary senescence: Secondary senescence/OIS upregulated genes; NIS: [@bib16] NIS/RIS upregulated genes; RIS: [@bib16] RIS/NIS upregulated genes.)Related to [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S4](#mmc5){ref-type="supplementary-material"}.

Third, we applied an unbiased genome-wide analysis. We calculated the enrichment of NIS and Ras-induced senescence (RIS) signatures in the primary OIS and secondary senescence transcriptomes by using gene set enrichment analysis (GSEA) ([@bib42]) on ranked transcriptome differences between NIS and RIS ([Figure 2](#fig2){ref-type="fig"}F). Secondary senescence signatures from the time course and co-culture experiments were highly enriched in NIS (normalized enrichment score \[NES\] = 2.61, false discovery rate \[FDR\] \< 0.005 for time course; NES = 2.89, FDR \< 0.005 for co-culture experiments; [Figure 2](#fig2){ref-type="fig"}F). Primary OIS transcriptomes showed an enrichment for RIS ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Finally, we interrogated the extent of NIS in secondary senescence by comparing the most differentially regulated genes (adjusted p \< 0.05) between RIS and NIS. We found a significant enrichment of NIS genes in our secondary senescence transcriptome in the time course and co-culture experiments, with primary OIS signature being enriched for RIS ([Figures 2](#fig2){ref-type="fig"}F and 2G; [Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). In summary, our data identify a pronounced NIS signature in secondary senescence and in a subset of primary senescent cells as an alternative endpoint to OIS.

NIS Is a Secondary Senescence Effector Mechanism during OIS {#sec1.3}
-----------------------------------------------------------

We next established Notch signaling as an effector mechanism in secondary senescence. We generated IMR90 fibroblasts with compromised Notch signaling by introducing a dominant-negative form of mastermind-like protein 1 fused to mVenus (mVenus:dnMAML1) or empty vector (mVenus:EV) control and co-cultured with ER:Ras IMR90 cells in the presence of tamoxifen ([Figure 3](#fig3){ref-type="fig"}A). At day 7 co-culture, mVenus:dnMAML1 compared to mVenus:EV cells exhibited lower expression of extracellular matrix gene *COL3A1* (p = 0.02) and Notch target *CTGF* (p = 0.056; [Figure S3](#mmc1){ref-type="supplementary-material"}A) as measured by qPCR, confirming impaired Notch signaling. Several lines of evidence show causal involvement of Notch signaling in secondary senescence. First, we scored mVenus (YFP) signal between mVenus:dnMAML1 and mVenus:EV cells at day 0 (growing) and day 7 co-culture with ER:Ras. At day 7, we observed significantly more mVenus:dnMAML1 compared to mVenus:EV cells (p = 0.01), suggesting that primary OIS cells have less secondary senescence effect on neighboring cells when harboring perturbed Notch signaling ([Figure S3](#mmc1){ref-type="supplementary-material"}B). No significant difference in mVenus-positive cells was observed in growing mVenus:EV compared to mVenus:dnMAML1 cells (p = 0.38), showing that the dnMAML1 itself does not affect cell numbers ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Second, we scored EdU incorporation between mVenus:dnMAML1 and mVenus:EV cells at days 0 and 7 ([Figure 3](#fig3){ref-type="fig"}B). At day 7, we observed significantly more EdU incorporation in mVenus:dnMAML1 compared to mVenus:EV cells (p = 0.01), with day 7 mVenus:dnMAML1 cells showing similarly high levels of EdU incorporation as growing mVenus:dnMAML1 and growing mVenus negative ER:Ras conditions (p = 0.997 and p = 0.08), suggesting that the induction of secondary senescence was abolished due to Notch perturbation ([Figure 3](#fig3){ref-type="fig"}B). As expected, ER:Ras cells showed low levels of EdU incorporation at day 7 tamoxifen (p = 0.01 for ER:Ras/mVenus:dnMAML1 co-culture and p = 0.0005 for ER:Ras/mVenus:EV co-culture; [Figure 3](#fig3){ref-type="fig"}B).Figure 3NIS Mediates Secondary Senescence *In Vitro*(A) Schematic representation of co-cultures with perturbed Notch signaling.(B) Bar plot for EdU incorporation in growing (black) or senescent (gray) EV or dnMAML1 cells co-cultured with ER:Ras as proportion of all cells scored. Error bars are displayed as SEM; F\[7,16\] = 20.63, p \< 0.001, one-way ANOVA with Tukey's test. (n = 3 per condition). Representative images are shown.(C) Scmap cluster projection of the dnMAML1 and EV 10× scRNA-seq dataset to the GFP co-culture 10× scRNA-seq dataset (see [Figure 1](#fig1){ref-type="fig"}H).(D) tSNE plot of single cells colored by the projection toward the GFP co-culture 10× dataset (see [Figure 1](#fig1){ref-type="fig"}H). Pie charts show percentage of cells.(E) GSEA pre-ranked test for enrichment of Notch signaling in mVenus:EV identified as secondary senescence by scmap.(F) Heatmap of single-cell data comparing mVenus:EV and mVenus:dnMAML1 for collagens and SASP genes. Red, upregulated and blue, downregulated.(G) GSEA pre-ranked test for enrichment of SASP genes in mVenus:dnMAML1 identified as secondary senescence by scmap.(H) GSEA pre-ranked test for enrichment of E2F targets in mVenus:dnMAML1 identified as secondary senescence by scmap.(I) Schematic representation of transwell co-culture assay of OIS and GFP cells.(J) Heatmap of significantly differentially expressed genes (p \< 0.05) between GFP contact and GFP no contact cells.(K) GSEA pre-ranked analysis for enrichment of Notch signaling in GFP contact cells compared to GFP no contact cells.(L) Pathway analysis for DE genes between GFP contact/GFP no contact (p \< 0.05).(M) GSEA pre-ranked analysis for enrichment of E2F targets in GFP no contact compared to GFP contact cells. Leading edge genes are indicated.Related to [Figure S3](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc3){ref-type="supplementary-material"}.

Third, we investigated SAHF in primary OIS and secondary senescence. Primary OIS cells displayed SAHF as expected (p = 4.437 × 10^−6^; [Figure S3](#mmc1){ref-type="supplementary-material"}C). Secondary senescent cells (mVenus:EV) did not show significant SAHF formation when compared to OIS (p = 0.32; [Figure S3](#mmc1){ref-type="supplementary-material"}C). This is consistent with published data where impaired Notch signaling partially suppresses SAHF formation in primary senescence ([@bib34]). In summary, we show that Notch signaling mediates secondary senescence *in vitro*.

To establish transcriptional differences between secondary senescence with and without Notch signaling, we generated scRNA-seq data from IMR90 mVenus:EV and mVenus:dnMAML1 co-cultures with ER:Ras IMR90 at day 7 tamoxifen. To integrate this dataset with our previous secondary senescence transcriptomes ([Figure 1](#fig1){ref-type="fig"}H), we projected the mVenus:EV and mVenus:dnMAML1 using Scmap ([@bib23]). Scmap clearly matches all primary senescent cells containing RasV12 to the OIS population ([Figure 3](#fig3){ref-type="fig"}C) and identifies significantly more secondary senescence cells in mVenus:EV compared to mVenus:dnMaml1 ([Figure 3](#fig3){ref-type="fig"}C; 37% versus 24%, chi-square test, p = 0.00062), confirming a role of Notch in secondary senescence. To explore transcriptomic differences between secondary senescence, we plotted all cells using Seurat, which separated mVenus:EV and mVenus:dnMAML1 into distinct secondary senescence clusters ([Figure 3](#fig3){ref-type="fig"}D). We confirmed differences in the activation of Notch pathway between mVenus:EV and mVenus:dnMaml1 by GSEA analysis ([Figure 3](#fig3){ref-type="fig"}E; NES = −1.35) and on the gene level for fibrillar collagens ([Figure 3](#fig3){ref-type="fig"}F; p \< 0.05). Notch signaling blunts the cytokine response in senescence as SASP factors ([Figure 3](#fig3){ref-type="fig"}G; NES = 1.1) and the interferon-gamma response ([Figure S3](#mmc1){ref-type="supplementary-material"}D; NES = 1.48) are differentially regulated between mVenus:EV and mVenus:dnMaml1, as judged by GSEA. Importantly, E2F targets, whose downregulation is one of the hallmarks of senescence, are upregulated in mVenus:dnMaml1 cells compared to mVenus:EV ([Figure 3](#fig3){ref-type="fig"}H; p = not significant \[n.s.\]) ([@bib31]), which offers an explanation for the strong phenotype differences we observed between the two conditions (see [Figure 3](#fig3){ref-type="fig"}B).

Notch induces senescence in a juxtacrine manner through cell-to-cell contact. We performed transwell experiments to verify the effect of cell-to-cell contact on the secondary senescence transcriptome. We co-cultured ER:Ras cells with GFP cells (GFP contact; [Figure 3](#fig3){ref-type="fig"}I) and GFP cells on their own in the transwell of the same well (GFP no contact). In this setting, GFP no contact cells shared media with ER:Ras cells, where cytokines can be transferred but no cell-to-cell contact is possible. We performed bulk RNA-seq of GFP contact and no contact cells 7 days after tamoxifen induction and confirmed enhanced expression of previously observed marker genes for NIS secondary senescence in GFP contact cells ([Figure 3](#fig3){ref-type="fig"}J). In addition, GSEA confirmed enrichment of Notch (NES = 1.59, FDR q = 0.019) and TGFB (NES = 1.87, FDR q = 0.0016) signaling ([Figures 3](#fig3){ref-type="fig"}K and [S3](#mmc1){ref-type="supplementary-material"}E) in GFP contact cells. Pathway analysis confirmed significant upregulation of previously described senescence pathways, such as "Senescence and Autophagy in Cancer" and "Matrix Metalloproteases" in GFP contact compared to GFP no contact cells ([Figure 3](#fig3){ref-type="fig"}L). Equally, GSEA showed repression of E2F target genes in GFP contact compared to GFP no contact fibroblasts ([Figure 3](#fig3){ref-type="fig"}M) except for E2F7, which is known to be upregulated in senescence ([Figure 3](#fig3){ref-type="fig"}J) ([@bib5]). GSEA analysis suggests that the global differences between GFP contact and no contact cells resemble the differences between mVenus:EV and mVenus:dnMaml1 secondary senescence ([Figure S3](#mmc1){ref-type="supplementary-material"}F).

OIS induction is a multi-step process with an early proliferative phase at days 1--3, followed by a phenotype transition phase at days 3--5, and established senescence from day 7 after RasV12 expression ([@bib48]). To compare the impact of the different phases of primary OIS onto secondary senescence, we co-cultured mVenus:EV or mVenus:dnMAML1 cells repeatedly with ER:Ras cells at days 3--6 or at days 7--10 after RasV12 induction ([Figure S3](#mmc1){ref-type="supplementary-material"}G). As expected, ER:Ras cells showed low levels of EdU incorporation in mVenus:dnMAML1 (day 7, p = 0.01) or mVenus:EV co-culture (day 7, p \< 0.001) ([Figures S3](#mmc1){ref-type="supplementary-material"}H and S3I) as a result of primary OIS. Co-culturing mVenus:EV with ER:Ras cells in the phenotype transition phase (days 3--5 after RasV12 induction) lead to a significant reduction in EdU when compared to uninduced co-cultures (p \< 0.001; [Figure S3](#mmc1){ref-type="supplementary-material"}H), suggesting that secondary senescence was induced by transition-phase primary OIS cells. The transition-phase effect is Notch-dependent because it cannot be induced in mVenus:dnMAML1 cells (p = 0.12; [Figure S3](#mmc1){ref-type="supplementary-material"}I). In contrast, by co-culturing mVenus:EV cells with primary OIS cells in established senescence phase (days 7--10 after RasV12 induction), we were unable to detect a reduction in EdU incorporation in mVenus:EV cells compared to uninduced co-cultures (p = 0.59; [Figure S3](#mmc1){ref-type="supplementary-material"}H), mirroring results obtained in mVenus:dnMAML1 co-cultures (p = 0.99; [Figure S3](#mmc1){ref-type="supplementary-material"}I). From day 4 co-culture, we detected a significant upregulation of Notch1 on the cell surface of mVenus:EV (p = 0.041 day 4, p = 0.038 day 7; data not shown) and mVenus:dnMaml1 (p = 0.023 day 4, p = 0.046 day 7; data not shown) cells compared to growing, providing a pathway to NIS induction ([Figure S3](#mmc1){ref-type="supplementary-material"}J). These results highlight a need for ER:Ras fibroblasts to be in phenotype transition phase to mediate secondary senescence by Notch1. Overall, our data identify Notch as a key mediator of secondary senescence.

Secondary Senescent Hepatocytes Are Characterized by NIS Signature {#sec1.4}
------------------------------------------------------------------

To test the involvement of NIS *in vivo*, we used a model where primary senescence is induced in a subpopulation of hepatocytes following *Mdm2* deletion ([@bib7]). This model is activated by hepatocyte-targeted recombination of *Mdm2* (β-napthoflavone \[βNF\] induction AhCre, Mdm2−), resulting in primary senescence in *Mdm2*− cells. *Mdm2*− hepatocytes induce secondary senescence in neighboring hepatocytes ([@bib7]) ([Figure 4](#fig4){ref-type="fig"}A). In this model, the presence of p53 induction through *Mdm2* deletion with medium levels of CDKN1A (non-senescence/primary p \< 0.001) marks primary senescence induction ([@bib7]) ([Figure 4](#fig4){ref-type="fig"}B; [Figure S4](#mmc1){ref-type="supplementary-material"}A and S4B). Physiological levels of P53 and high levels of CDKN1A (CDKN1A expression secondary/primary p \< 0.0001) marks secondary senescence in *Mdm2* normal (*Mdm2*+) hepatocytes as described ([@bib7]) ([Figure 4](#fig4){ref-type="fig"}B). Based on these characteristics, cells can be readily distinguished by immunohistochemistry with 23% of primary and 10% of secondary senescence hepatocytes detected ([Figure S4](#mmc1){ref-type="supplementary-material"}A). We have previously shown that both subpopulations of hepatocytes upregulate senescence markers (gH2AX, Il1A, SA-Beta Gal) and reduce BrdU incorporation ([@bib7]).Figure 4Notch Signaling Mediates Secondary Senescence *In Vivo*(A) Schematic representation of *in vivo* single-cell experiment.(B) Representative immunofluorescence images of liver section from induced AhCre+Mdm2fl/fl and control AhCre^WT^Mdm2^fl/fl^ mice stained for p53 and CDKN1A. Intrinsically induced senescence (arrowhead) and secondary senescence (arrow) are indicated. Boxplot for CDKN1A intensity in primary versus secondary senescent cells. (senescence: F\[1,50291\] = 2766, p \< 0.0001; biological replicates: F\[2,50291\] = 283.2, p \< 0.0001; senescence × biological replicates: F\[2,50291\] = 280.5, p \< 0.0001, two-way ANOVA). Scale bar, 22 μm.(C) Pathway analysis for *Mdm2*+ (secondary) genes.(D) GSEA for *Mdm2*+/*Mdm2−* cells (NES = 1.07). Leading edge genes are indicated.(E) Heatmap for Notch pathway, hepatocyte markers, and *Cdkn1a* genes in *Mdm2*+ and *Mdm2−* cells. Constitutive genes and *Cdkn1a* were colored by their expression relative levels (binary: red expressed, white not expressed).(F) SCDE for *Maml1*, *Rfng*, and *Smad3* in *Mdm2*+ cells (orange lines) and *Mdm2−* cells (blue lines). Joint posterior is marked by black line. Fold change of the genes in *Mdm2*+/*Mdm2−* is indicated in red, and dotted lines mark the 95% confidence interval. MLE, maximum likelihood estimation; CI, confidence interval; Z, *Z* score.(G) Representative immunofluorescence images of liver section from induced and control mice. Primary senescent cells (arrowheads) and secondary senescent cells (arrows) are indicated (CDKN1A: F\[1,60145\] = 353.3, p \< 0.0001; biological replicates: F\[2,60145\] = 1044, p \< 0.0001; CDKN1A × biological replicates: F\[2,60145\] = 8.96, p \< 0.0001, two-way ANOVA). Scale bar, 22 μm.Related to [Figure S4](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}.

To establish if primary and secondary senescence can be distinguished based on the transcriptome *in vivo*, we performed scRNA-seq on hepatocytes using Smart-Seq2 ([Figure 4](#fig4){ref-type="fig"}A). After filtering ([Figure S4](#mmc1){ref-type="supplementary-material"}B and S4C; [Table S1](#mmc2){ref-type="supplementary-material"}), we retained 39 single cells from induced *Mdm2*-deleted mouse liver for downstream analysis. We distinguished *Mdm2−* cells from *Mdm2*+ hepatocytes by the absence of mapping reads over exon 5 and 6 of the *Mdm2* gene ([Figure S4](#mmc1){ref-type="supplementary-material"}D). We detected expression of *Cdkn1a* in both senescent populations consistently with the differences in CDKN1A protein levels detected by immunohistochemistry ([Figure 4](#fig4){ref-type="fig"}B), with lower (but not significant) *Cdkn1a* expression in *Mdm2−* compared to *Mdm2*+ hepatocytes ([Figure S4](#mmc1){ref-type="supplementary-material"}E), enabling us to distinguish primary and secondary senescence. To verify a senescence phenotype in both *Mdm2−* and *Mdm2*+ hepatocyte populations, we conducted pathway analysis with upregulated pathways being enriched in p53 signaling, including CDKN1A, DNA damage response, and cytokine signaling ([Figure S4](#mmc1){ref-type="supplementary-material"}F). We next asked if NIS plays a role in secondary senescence *in vivo* by analyzing our single-cell data by using three independent methods. Differentially expressed genes between *Mdm2*+ and *Mdm2−* cells were identified using single cell differential expression (SCDE) ([Table S2](#mmc3){ref-type="supplementary-material"}), and genes were ranked between *Mdm2*+/*Mdm2−* cells for downstream analysis. First, pathway analysis revealed enrichment in Notch signaling (ratio of enrichment \[RE\], 7.07), Delta-Notch signaling (RE, 4.63), and TGFB (RE, 4.11) signaling pathways ([Figure 4](#fig4){ref-type="fig"}C). Second, GSEA revealed Notch signaling pathway (NES = 1.07) as one of the top 20 Kegg pathways enriched in Mdm2+/Mdm2− ([Figure 4](#fig4){ref-type="fig"}D) with leading edge genes *Maml1* and *Jag2* detectable mainly in Mdm2+ cells (Fisher's exact test = 6.93 × 10^−7^; [Figure 4](#fig4){ref-type="fig"}E). Housekeeping and hepatocyte-specific genes were expressed to the same level in the majority of cells regardless of Mdm2 status ([Figure 4](#fig4){ref-type="fig"}E). Third, SCDE analysis confirmed the specific upregulation of Notch and TGFB targets *Maml1* (adjusted *Z* score \[aZ\] = 0.4) and *Rfng* (aZ = 0.39) with effector protein *Smad3* (aZ = 0.26) in *Mdm2*+ compared to *Mdm2−* hepatocytes ([Figure 4](#fig4){ref-type="fig"}F). To assess the proposed TGFB and CEBPB bias between primary and secondary senescence *in vivo*, we stained livers from uninduced and induced mice for CDKN1A and CEBPB by immunohistochemistry. Consistent with our *in vitro* data, we observed significantly higher CEBPB protein in primary (p \< 0.0001; [Figure 4](#fig4){ref-type="fig"}G) compared to secondary senescent hepatocytes. These lines of evidence show that secondary senescent hepatocytes are characterized by a NIS signature *in vivo*.

Discussion {#sec2}
==========

Cancer heterogeneity is an expanding field of research, with little knowledge about cellular heterogeneity in a pre-cancerous state. Are all cells reacting similarly to oncogene activation or does an oncogenic insult result in a heterogeneous population? Understanding heterogeneity in a pre-cancerous state will inform distinct propensities for transformation in subpopulations. Our study uncovers heterogeneity in primary OIS and secondary senescence transcriptomes following an oncogenic insult using single-cell approaches.

Paracrine induction of senescence is thought to be the main mediator of secondary senescence in OIS ([@bib2], [@bib24]). Our results challenge this canonical view implicating NIS as a synergistic driver of secondary senescence *in vitro*, in the most studied OIS background (RasV12) and in the liver *in vivo*.

Primary and secondary senescent cells are not thought of as functionally distinct endpoints. We provide strong evidence for differences between primary OIS and Notch-mediated juxtacrine secondary senescence, as they display distinct gene expression profiles and potentially different transformation potential ([@bib2], [@bib16]). Some of our findings point to a functional diversification, for example, the blunted SASP response and the induction of fibrillar collagens in secondary senescence compared to OIS.

We identified two transcriptional endpoints for primary OIS, namely a Ras-driven and a NIS program. Notch signaling is mediated through cell-to-cell contact (juxtacrine), and [@bib16] have shown that it can be a transient state toward primary senescence induction. Our data indicate cells carrying a composite transcriptional signature of paracrine and juxtacrine events as a facultative endpoint for cells with detectable Ras activation (primary). The transformation potential of these heterogeneous populations needs addressing.

STAR★Methods {#sec3}
============

Key Resources Table {#sec3.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rat monoclonal anti-p21 (Cdkn1a)Originally gift from Serrano lab CNIO, Madrid, now available at AbcamHUGO291-T3413C/EBPB clone 1H7AbcamCat\# ab15050; RRID:[AB_301598](nif-antibody:AB_301598){#interref205}NCL-L-p53-CM5pLeica BiosystemsCat\# P53-CM5P-L; RRID:[AB_2744683](nif-antibody:AB_2744683){#interref210}Notch1-PE FAB5317PR&D systemsCat\# FAB5317P-025; RRID:[AB_1602927](nif-antibody:AB_1602927){#interref215}Mouse monoclonal anti-p53Cell Signaling TechnologyCat\#2524; RRID:[AB_331743](nif-antibody:AB_331743){#interref220}VECTASTAIN® Elite® ABC HRP ReagentVector LabsPK-7100; RRID:[AB_2336827](nif-antibody:AB_2336827){#interref225}TSA Plus Fluorescein Evaluation Kit - FITCPerkin ElmerNEL741B001KTTSA Plus Fluorescein Evaluation Kit -- Cy3Perkin ElmerNEL744B001KTBiotinylated polyclonal goat anti ratVector LabsBA-9400; RRID:[AB_2336202](nif-antibody:AB_2336202){#interref230}Biotinylated polyclonal horse anti mouseVector LabsBA-2000; RRID:[AB_2313581](nif-antibody:AB_2313581){#interref235}C/EBPB clone E299AbcamCat\# ab 32358; RRID:[AB_726796](nif-antibody:AB_726796){#interref240}**Chemicals, Peptides, and Recombinant Proteins**4-hydroxytamoxifenSigmaCat\# H62787-AADBiolegendCat\# 420403DAPIBiolegendCat\# 422801β-NaphthoflavoneSigmaCat\# N3633**Critical Commercial Assays**Tetro cDNA synthesis kitBiolineCat\# BIO-65043Click-iT EdU Alexa Fluor 555 imaging kitClick-iT EdU Alexa Fluor 555 imaging kitCat\# 32727RNeasy Mini KitQIAGENCat\# 74104Chromium Single Cell 3′ Library & Gel Bead Kit v210xGenmicsCat\# 120237Chromium i7 Multiplex Kit10xGenomicsCat\# 120262Chromium Single Cell 3′ Chip Kit v210xGenomicsCat\# 120236**Deposited Data**All single cell RNA-seq datasetsThis paperGEO: [GSE115301](ncbi-geo:GSE115301){#intref0010}Bulk RNA-seq dataThis paperGEO: [GSE115301](ncbi-geo:GSE115301){#intref0015}Raw Imaging dataThis paperMendeley dataset [https://doi.org/10.17632/y76pb7s8h3.1](10.17632/y76pb7s8h3.1){#intref0020}.**Experimental Models: Cell Lines**IMR90 normal human diploid fibroblastsATTCATCC Cat\# CRL-7931, RRID:CVCL_0347**Experimental Models: Organisms/Strains**Mouce: AhCre+, Mdm2^flox/flox^[@bib7]N/A**Oligonucleotides**Primers for qPCR, see [Table S3](#mmc4){ref-type="supplementary-material"}This paperN/A**Recombinant DNA**pLNCX2 ER:rasAddgene, [@bib48]Plasmid \#67844pLPC-puro dnMAML1-mVenusa kind gift from M. Narita to J.C.A.[@bib16]pLPC-puro -mVenusa kind gift from M. Narita to J.C.A.[@bib16]pGIPZ-GFPa kind gift from M. Narita to J.C.A.[@bib16]**Software and Algorithms**TrimGaloreBabraham Institute<http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/> RRID:[SCR_016946](rridsoftware:SCR_016946){#intref0030}HTSeq-0.6.1[@bib6]<https://htseq.readthedocs.io/en/release_0.11.1/overview.html> RRID:[SCR_005514](rridsoftware:SCR_005514){#intref0040}Cell Ranger 2.0.110xGenomics<https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/what-is-cell-ranger>FreeBayes v0.9.20-8-gfef284a[@bib15]<https://github.com/ekg/freebayes> RRID:[SCR_010761](rridsoftware:SCR_010761){#intref0055}HISAT v2.0.1beta[@bib19]<http://ccb.jhu.edu/software/hisat2/index.shtml> RRID:[SCR_015530](rridsoftware:SCR_015530){#intref0065}Monocle2[@bib36]<http://cole-trapnell-lab.github.io/monocle-release/docs/> RRID:[SCR_016339](rridsoftware:SCR_016339){#intref0075}SC3[@bib22]<http://bioconductor.org/packages/release/bioc/html/SC3.html> RRID:[SCR_015953](rridsoftware:SCR_015953){#intref0085}WebGestalt[@bib44]<http://www.webgestalt.org/> RRID:[SCR_006786](rridsoftware:SCR_006786){#intref0095}Gene Set Enrichment Analysis[@bib42]<http://software.broadinstitute.org/gsea/index.jsp> RRID:[SCR_003199](rridsoftware:SCR_003199){#intref0105}DESeq2[@bib26]<https://bioconductor.org/packages/release/bioc/html/DESeq2.html> RRID:[SCR_015687](rridsoftware:SCR_015687){#intref0115}samtools/1.2 mpileup[@bib25]<http://www.htslib.org/> RRID:[SCR_002105](rridsoftware:SCR_002105){#intref0125}SCDE v1.99.1[@bib18]<http://hms-dbmi.github.io/scde/index.html> RRID:[SCR_015952](rridsoftware:SCR_015952){#intref0135}Seurat 2.3.0<http://seurat.r-forge.r-project.org/> RRID:[SCR_007322](rridsoftware:SCR_007322){#intref0145}sparcl 1.0.3[@bib46]<https://cran.r-project.org/web/packages/sparcl/index.html>

Contact for Reagent and Resource Sharing {#sec3.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Tamir Chandra (<tamir.chandra@igmm.ed.ac.uk>).

Experimental Model and Subject Details {#sec3.3}
--------------------------------------

### Animal models {#sec3.3.1}

Animal welfare conditions have been previously described ([@bib27]). All animal experiments were carried out on healthy, treatment naive animals under procedural guidelines, severity protocols and within the UK with ethical permission from the Animal Welfare and Ethical Review Body (AWERB) and the Home Office (UK). AhCre+/WT *Mdm2*fl/fl and AhCreWT/WT *Mdm2*fl/fl mice (colony N4 C57/Bl6J background) were crossed. Male littermates were housed together, and when used in experiments were all \> 20 g body weight and of 10-16 weeks age. Genotyping and single i.p. injection of β-Naphthoflavone (βNF, Sigma UK) at 20mg/kg were performed as previously described ([@bib7]).

### Cell culture {#sec3.3.2}

We used normal diploid human female lung fibroblasts IMR90 isolated at 16 weeks of gestation for all *in vitro* assays (ATCC^®^ CCL-186). pLNCX2-ER:ras^G12V^-expressing IMR90 (plasmid obtained from Addgene \#67844) were maintained and senescence induced as described under 5% O~2~ conditions ([@bib48]). ER:IMR90 cells were co-cultured with IMR90:GFP (pGIPZ-GFP, a kind gift from M. Narita to J.C.A.) or an empty vector fused with mVenus (pLPC-puro-mVenus, a kind gift from M. Narita to J.C.A.) or with a dominant negative form of MAML1 fused with mVenus (pLPC-puro-dnMAML1-mVenus, a kind gift from M. Narita to J.C.A.) cells at 10:1 ratio.

Method Details {#sec3.4}
--------------

### Hepatocyte isolation {#sec3.4.1}

*Ex vivo* primary hepatocytes were isolated using a modified retrograde perfusion technique as previously described ([@bib27]). Hepatocytes were purified by pelleting through a 40% (v:v) percoll gradient prior to FACS sorting.

### Immunohistochemistry {#sec3.4.2}

Mouse livers were harvested and partially stored in paraffin blocks following fixation in 10% formalin (in PBS) for 18 hours prior to embedding. Immunohistochemistry was performed as described ([@bib7]). Three μm thick paraffin sections were double stained for p53/CDKN1A and CDKN1A and CEBPB using the CDKN1A clone HUGO291H (a gift from Serrano lab, CNIO in Madrid), and either C/EBPB clone 1H7 (Abcam) or p53 clone 1C12 (Cell Signaling). Detection was performed with TSA-Cy3 (Perkin Elmer, NEL744B001KT, 1:50) and TSA-FITC (Perkin Elmer, NEL741B001KT, 1:50). Images were captured on a Zeiss 710 Upright Confocal Z6008 microscope. Stained slides were scanned using the Opera Phoenix High Content screening system (Perkin Elmer) scanner and analyzed using the Columbus software.

### Transwell assay {#sec3.4.3}

ER:Ras^G12V^-expressing cells were co-cultured with IMR90:GFP cells. The co-cultured cells were placed into the lower chamber of a transwell system (density 5x10^3^ cells/well). Another pure population of IMR90:GFP cells were cultured in the upper chamber of the transwell system. All cells were maintained in 4-hydroxytamoxifen (Sigma) for 7 days. All experiments were performed in triplicate.

### Flow cytometry {#sec3.4.4}

Flow cytometry was performed with three independent replicates as previously described ([@bib21]) using 7-AAD (Biolegend), DAPI (Biolegend) and anti-Notch1-PE (R&D systems, FAB5317P, 1:20). Analysis was performed on the BD FACSAria II (BD Biosciences, San Jose, CA) using the BD CellQuest PRO software (BD Biosciences, San Jose, CA). Flow data were analyzed with FlowJo v10 (Tree Star, Ashland, OR).

### RNA extraction {#sec3.4.5}

RNA from three to four independent experiments was extracted using the RNeasy Mini Kit (QIAGEN). All RNA passed with a RIN of 9 or above as determined by Bioanalyser profiling. Ribosome depletion was performed prior to bulk RNA sequencing.

### qPCR {#sec3.4.6}

cDNA was generated as previously described using the Tetro cDNA synthesis kit (Bioline) ([@bib20]). qPCR was performed on a LightCycler 480 (Roche) using Sybr Green method as previously described ([@bib20]). Primer sequences are in [Table S3](#mmc4){ref-type="supplementary-material"}.

### EdU incorporation and SA-Beta Gal staining {#sec3.4.7}

EdU incorporation and SA-Beta gal staining was performed as previously described ([@bib20]). EdU incorporation was detected using the Click-iT EdU Alexa Fluor 555 imaging kit (ThermoScientific). For stable cell cycle arrest, cells were co-cultured for two weeks, separated by FACS according to GFP status and cultured as OIS and GFP cells for another week before pulsing them with EdU for 24 hours.

### Immunofluorescence {#sec3.4.8}

Immunoflurorescence was performed as previously described ([@bib20]). Anti- C/EBPB clone E299 (Abcam) was used as 1:500 dilution.

### Confocal microscopy and Image analysis {#sec3.4.9}

BriteMac confocal microscope was used to visualize cells at 40x. Images were analyzed using ImageJ. Percentages of SAHF, YFP/GFP and EdU-positive cells were calculated by assessing 1600-2000 cells per experiment from three independent experiments.

### Single cell data generation {#sec3.4.10}

Smart-Seq2 was performed on sorted ER:IMR90 cells or hepatocytes as previously described ([@bib21]). Single cell data for all co-culture experiments were generated using the Chromium Single Cell 3′ Chip Kit v2 (10xGenomics), following the manufacturer's instructions.

Quantification and Statistical Analysis {#sec3.5}
---------------------------------------

### Bioinformatics analysis {#sec3.5.1}

#### Sequencing reads processing, alignment and quantification of time-course experiment {#sec3.5.1.1}

Smart-Seq2 generated paired-end reads were quality trimmed using Trim galore (<http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/>) and aligned to the human reference genome, hg19, neomycin sequence from pLNCX2-ER-ras_neo, ERCC spike-in sequences and RasV12 using HISAT v2.0.1beta ([@bib19]). Cells with less than 200,000 hg19 aligned reads, and a ratio of ERCC RNA spike-in control aligned reads to total aligned reads greater than 0.5 were omitted. hg19 aligned reads were randomly downsampled to 200,000 reads. Genes were quantified using HTSeq-0.6.1 ([@bib6]). Cells with more than 80,000 total gene counts and at least 500 genes with at least one count were used for downstream analysis. 224 IMR90 cells (100 Growing cells, 41 Day 2 cells, 42 Day 4 cells and 41 senescent cells) passed this second filtering step and used for downstream analyses.

#### Sequencing reads processing, alignment, quantification and analysis of 10x Chromium RNA-seq data {#sec3.5.1.2}

Cell Ranger 2.0.1 (10x Genomics) was used to align the GFP and ER:Ras^G12V^ co-culture 10x Chromium RNA-seq reads to hg19, TurboGFP, puromycin sequence from pGIPZ and neomycin sequence from pLNCX2-ER-ras_neo, and to generate gene-cell matrices. The growing and senescence dataset were aggregated using "cellranger aggr." The data were subsequently processed using Seurat 2.3.0 with cells with less than 15% mitochondrial reads and at least 2500 number of genes being retained ([@bib9]). Seurat 2.3.0 with the default parameters (unless otherwise stated) was used to generate the t-SNE plots (resolution:0.4; dimensions used: 1:15) and three clusters were identified using sparcl 1.0.3 (<https://cran.r-project.org/web/packages/sparcl/index.html>). SCDE v1.99.1 was used to identify differentially expressed genes between OIS cluster and secondary senescent cluster ([@bib18]). The DE genes (p values \< 0.05) ([Table S2](#mmc3){ref-type="supplementary-material"}) were used as the defined gene sets for GSEA Preranked analysis of NIS and RIS log2FC ranked genes. GFP+ cells were identified as cells with \> 0.3 normalized expression of GFP or puromycin and Ras+ cells were identified as cells with non-zero expression of neomycin or one or more reads supporting the G \> T mutation at Chr11:534288 as identified by FreeBayes v0.9.20-8-gfef284a ([@bib15]). Integration analysis between Smart-seq2 time-point data and 10x data were performed using the canonical correlation analysis in Seurat 2.3.0, in which the union of the top 50 highest dispersion genes and the first two dimensions were used.

Cell Ranger 2.0.1 (10x Genomics) was used to align the 10x Chromium RNA-seq reads from mVenus:dnMAML1 or mVenus:EV co-cultured with ER:Ras^G12V^ cells to hg19, mVenus sequence, puromycin sequence from pLPC-puro and neomycin sequence from pLNCX2-ER-ras_neo to generate gene-cell matrices. mVenus cells were identified as cells with more than zero normalized expression of mVenus or puromycin and Ras+ cells were identified as cells with non-zero expression of neomycin or one or more reads supporting the G \> T mutation at Chr11:534288 as identified by FreeBayes v0.9.20-8-gfef284a ([@bib15]). The data were subsequently processed using Seurat 2.3.0 with cells with less than 10% mitochondrial reads and at least 2500 genes being retained. Seurat 2.3.0 with the default parameters (unless otherwise stated) was used to generate the tSNE plots (resolution:0.6; dimensions used: 1:7). The cells were projected to the 10x Chromium GFP and ER:Ras^G12V^ co-culture dataset using scmap-cluster v1.4.1.

#### Sequencing reads processing, alignment and quantification of *in vivo* data {#sec3.5.1.3}

Smart-Seq2 generated paired-end reads were quality trimmed using Trim galore (<http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/>) and aligned to the mouse reference genome mm10 and ERCC spike-in sequences using HISAT v2.0.1beta ([@bib19]). The mm10 aligned reads were randomly downsampled to 50,000 reads. Cells with less than 50,000 reads, less than 20,000 gene count, less than 500 genes with at least one read detected and with the log-transformed number of expressed genes and library size of 3 median absolute deviation below the median value were removed ([@bib28]). 39 single cells from the induced hepatocytes and 19 cells from the uninduced hepatocytes passed these filters. 22 primary senescent cells were identified from the induced hepatocytes as cells with no reads mapping over exon 5 and 6 (chr10:117695953-117696049, chr10:117696381-117696439, chr10:117701565-117701614 and chr10:117702202-117702335) of *Mdm2* gene before the downsampling. 17 cells were classified as secondary hepatocytes as judged by their gene expression profiles. Differential genes expression between *Mdm2*+ cells and *Mdm2*- cells was identified using SCDE v1.99 and log2FC ranked gene list from SCDE was used in GSEA pre-ranked analysis. Genes with more than zero log-transformed normalized count ([@bib29]) were labeled red, and otherwise white in the binary heatmap. Pathway enrichment was identified using WebGestalt ([@bib44]) with genes that have a z-score of greater than 2 in *Mdm2*+ cells /*Mdm2*- comparison.

#### Differential gene expression analysis and temporal ordering of cells {#sec3.5.1.4}

We used raw counts from HTSeq-0.6.1 ([@bib6]) as an input to single-cell differential expression (SCDE v1.99.1) ([@bib18]) for differential gene expression analysis between growing and senescence. Cut-off for significantly differentially expressed (DE) was set at 0.05. The expression magnitude (fragments per million) was obtained from SCDE and converted to FPKM as an input for Monocle2 ([@bib36]). Monocle2 was used to order the transitions of senescent cells of different time points at a pseudo-temporal resolution, and single-cell data were reduced to a 2-dimensional space by using the DDRTree algorithm implemented in Monocle2 ([@bib36]). Specifically, DE genes between senescence and growing conditions that were identified in SCDE were used to define the trajectory. A consensus clustering approach, SC3, was also applied to the raw count of single cells and used to cluster senescent cells ([@bib22]).

#### Detection of Ras^V12^ construct in Smart-seq2 dataset {#sec3.5.1.5}

We counted reads with a G \> T mutation at Chr11:534288 using samtools v1.2 mpileup and bcftools v1.2 ([@bib25]). Cells with more than 1 read supporting over G \> T mutation or at least 9 reads mapping to the neomycin sequence are considered as Ras^V12^ positive cells.

#### Paracrine-induced senescence and RIS microarray data analysis {#sec3.5.1.6}

Log2 RMA signal intensity of RIS IMR90 cells and IMR90 co-cultured in transwells with RIS cells were obtained from GEO [GSE41318](ncbi-geo:GSE41318){#intref0175}. Differentially expressed genes were identified using limma ([@bib37]) and an adjusted p value of 0.05 was used as the cut-off for significant genes.

#### Notch and Ras-induced senescence data and GSEA analysis {#sec3.5.1.7}

We used NIS and RIS RNA-seq data with accession number [GSE72404](ncbi-geo:GSE72404){#intref0180}. Reads were aligned to as described above. Differential gene expression analysis between NIS and RIS was performed using DESeq2 ([@bib26]). The log2 fold change for each gene was used to rank the list of genes in GSEA Preranked analysis ([@bib42]). Differentially expressed (DE) genes between senescence top and bottom were identified using SCDE with a p value cutoff of 0.05. The DE genes defined the gene set in GSEA Preranked analysis.

#### Sequencing reads alignment and quantification of transwell bulk RNA-sequencing data {#sec3.5.1.8}

Reads were aligned to the human reference genome hg19 using HISAT v2.0.1beta ([@bib19]) and those that mapped to annotated genes were quantified using HTSeq-0.6.1 ([@bib6]). Differential gene expression was determined using DESeq2 v1.22.1 ([@bib26]). Over-representation analysis was performed using WebGestalt ([@bib44]) and GSEA pre-ranked analysis was performed using the ranking of genes based on the log2FC between GFP contact and GFP no contact.

### Statistical analysis {#sec3.5.2}

All t tests and one-way ANOVA for the *in vitro* data were performed in R. TukeyHSD was used as the post hoc test for one-way ANOVA. For the *in vitro* data, each experiment and measurement were obtained from three independent experiments unless otherwise specified in the figure legends. Barplots are represented as means with SEM. Statistical significance was set at p \< 0.05. t test for the *in vivo* data was performed in R and the two-way ANOVA followed by Tukey's test for the *in vivo* data was performed using GraphPad Prism. All animal data were obtained from three biological replicates. Details of all statistical analysis can be found in associated figure legends. For qPCR analysis, Delta delta Ct method was used for quantification with error bars resulting from the delta Ct expression of three to four biological replicates. A two-sided t test was used to calculate p values.

Data and Software Availability {#sec3.6}
------------------------------

All scRNA-seq and bulk RNA-seq experiments are accessible through GEO accession number GEO: [GSE115301](ncbi-geo:GSE115301){#intref0185}. All imaging data are available as Mendeley dataset under [https://doi.org/10.17632/y76pb7s8h3.1](10.17632/y76pb7s8h3.1){#intref0190}.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S4Table S1. Alignment Rates and Quality Control of RNA Sequencing Data, Related to Figures 1 and 4Table S2. Differential Expression of RNA Sequencing Data, Related to Figures 1, 2, 3, and 4Table S3. Presence of Construct and qPCR Primer, Related to Figures 1, 2, 3, and 4Table S4. Genes for Venn Diagrams, Related to Figures 1 and 2Document S2. Article plus Supplemental Information

K.K. was supported by the Wellcome Trust (105641/Z/14/Z). T.C. was supported by a Chancellor's Fellowship held at the University of Edinburgh. N.R. was supported by a PhD studentship funded by the Wellcome Trust Sanger Institute (206194) and the Royal Thai Government. N.O. was supported by MRC (MC_PC_15075). The N.N. lab was partially supported by IDeA grant P20GM109035 (Center for Computational Biology of Human Disease) from NIH NIGMS and grant 1R01AG050582-01A1 from NIH NIA. Y.V.T. was funded by the American Federation for Aging Research. T.G.B. was funded by the Wellcome Trust (WT107492Z). C.K. was supported by CRUK Beatson Institute Core funding. P.D.A. was funded by P01 grant (AG031862) and by CRUK (C10652/A16566). Work in the Green laboratory was supported by Bloodwise, CRUK, and Wellcome Trust. J.-C.A. was supported by CRUK (C47559/A16243). We would like to thank the CRUK Beatson Histology core facility for help with immunohistochemistry and Prof. Chris Ponting and Dr. Andy Fynch for critical reading of the manuscript.

Author Contributions {#sec4}
====================

T.C., K.K., and N.N. conceived the study. Y.V.T. performed bioinformatics analysis. N.R. performed the experiments and data analysis with help from A.S., A.Q., N.T., N.O., and K.K. *In vivo* work and data analysis were carried out by C.K., M.M., and T.G.B. P.D.A., J.-C.A., and A.R.G. gave feedback on the study and manuscript. K.K., T.C., and Y.V.T. wrote the manuscript.

Declaration of Interests {#sec5}
========================

The authors declare no competing interests.

Supplemental Information can be found online at <https://doi.org/10.1016/j.celrep.2019.03.104>.

[^1]: These authors contributed equally

[^2]: Lead Contact
